-transparent.png){kind=logo}
A novel series of pazopanib derivatives were designed, synthesized, and evaluated for their inhibitory activity against a series of kinases including VEGFR-2, EGFR, AKT1, ALK1, and ABL1. The anti-angiogenic activities ex vivo of some compounds were also investigated. Compounds P2d and P2e demonstrated outstanding inhibitory activity against VEGFR-2 and ABL1 and higher anti-angiogenic activity compared with Pazopanib, the reference standard. These two compounds (P2d and P2e) could be used as novel lead compounds for further development of anticancer agents.
Related Publications
Yuping Jia, and
Jian Zhang, and
Jinhong Feng, and
Fuming Xu, and
Huili Pan, and
Wenfang Xu
February 2014,
Bioorganic & medicinal chemistry letters,
Yuping Jia, and
Jian Zhang, and
Jinhong Feng, and
Fuming Xu, and
Huili Pan, and
Wenfang Xu
December 2022,
Journal of enzyme inhibition and medicinal chemistry,
Yuping Jia, and
Jian Zhang, and
Jinhong Feng, and
Fuming Xu, and
Huili Pan, and
Wenfang Xu
September 2019,
European journal of medicinal chemistry,
Yuping Jia, and
Jian Zhang, and
Jinhong Feng, and
Fuming Xu, and
Huili Pan, and
Wenfang Xu
May 2024,
Bioorganic chemistry,
Yuping Jia, and
Jian Zhang, and
Jinhong Feng, and
Fuming Xu, and
Huili Pan, and
Wenfang Xu
January 2019,
Frontiers in chemistry,
Yuping Jia, and
Jian Zhang, and
Jinhong Feng, and
Fuming Xu, and
Huili Pan, and
Wenfang Xu
July 2014,
Molecules (Basel, Switzerland),
Yuping Jia, and
Jian Zhang, and
Jinhong Feng, and
Fuming Xu, and
Huili Pan, and
Wenfang Xu
September 2018,
Molecules (Basel, Switzerland),
Yuping Jia, and
Jian Zhang, and
Jinhong Feng, and
Fuming Xu, and
Huili Pan, and
Wenfang Xu
November 2020,
Bioorganic chemistry,
Yuping Jia, and
Jian Zhang, and
Jinhong Feng, and
Fuming Xu, and
Huili Pan, and
Wenfang Xu
May 2019,
Archiv der Pharmazie,
Yuping Jia, and
Jian Zhang, and
Jinhong Feng, and
Fuming Xu, and
Huili Pan, and
Wenfang Xu
April 2019,
MedChemComm,
